Should I buy or sell 2seventy bio stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 2seventy bio in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TSVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TSVT, but not buy additional shares or sell existing shares. View TSVT analyst ratings or view top-rated stocks .

What is 2seventy bio's stock price target for 2024?

8 analysts have issued 1-year price objectives for 2seventy bio's stock. Their TSVT share price targets range from $5.00 to $26.00. On average, they anticipate the company's share price to reach $13.17 in the next twelve months. This suggests a possible upside of 160.2% from the stock's current price. View analysts price targets for TSVT or view top-rated stocks among Wall Street analysts .

How have TSVT shares performed in 2024?

2seventy bio's stock was trading at $4.27 at the beginning of the year. Since then, TSVT stock has increased by 18.5% and is now trading at $5.06. View the best growth stocks for 2024 here .

Are investors shorting 2seventy bio?

2seventy bio saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 6,810,000 shares, an increase of 29.7% from the March 15th total of 5,250,000 shares. Based on an average daily volume of 1,450,000 shares, the short-interest ratio is currently 4.7 days. Currently, 14.3% of the company's stock are short sold. View 2seventy bio's Short Interest .

When is 2seventy bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our TSVT earnings forecast .

How were 2seventy bio's earnings last quarter?

2seventy bio, Inc. (NASDAQ:TSVT) posted its quarterly earnings results on Tuesday, March, 5th. The company reported ($1.11) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.11. The business had revenue of $10.68 million for the quarter, compared to analysts' expectations of $13.91 million. 2seventy bio had a negative trailing twelve-month return on equity of 59.19% and a negative net margin of 216.73%. During the same period in the prior year, the business earned ($0.60) earnings per share.

What ETFs hold 2seventy bio's stock?

ETFs with the largest weight of 2seventy bio (NASDAQ:TSVT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA) , Horizon Kinetics Medical ETF (MEDX) and Goldman Sachs Future Health Care Equity ETF (GDOC) . Global X Genomics & Biotechnology ETF (GNOM) .

Who are 2seventy bio's major shareholders?

2seventy bio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wedmont Private Capital (0.17%). Insiders that own company stock include Casdin Capital, Llc, Kynam Capital Management, Lp, Nick Leschly , Nicola Heffron , Philip D Gregory and William D Baird III . View institutional ownership trends .

How do I buy shares of 2seventy bio?

Shares of TSVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TSVT

2seventy bio (TSVT) Stock Price, News & Analysis

→ With the “Bitcoin Loophole” you can supercharge the gains by 10x or more (From DTI) (Ad)

Free TSVT Stock Alerts

$5.06

+0.20 (+4.12%)

(As of 04/17/2024 ET)

Compare

Today's Range: $4.87
▼
$5.20
50-Day Range: $3.96
▼
$6.00
52-Week Range: $1.53
▼
$12.69

Volume: 895,858 shs
Average Volume: 1.42 million shs
Market Capitalization: $259.63 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.17

Get 2seventy bio alerts:

2seventy bio MarketRank™ Stock Analysis

Analyst Rating: Hold
2.38 Rating Score
Upside/Downside: 160.2% Upside
$13.17 Price Target
Short Interest: Bearish
14.29% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.74
Based on 8 Articles This Week
Insider Trading: Acquiring Shares
$3.14 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.39) to $0.07 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.18 out of 5 stars

Medical Sector

271st out of 914 stocks

Pharmaceutical Preparations Industry

106th out of 406 stocks

4.2

Analyst's Opinion

Consensus Rating
2seventy bio has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 3 buy ratings, 5 hold ratings, and no sell ratings.
Amount of Analyst Coverage
2seventy bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
14.29% of the float of 2seventy bio has been sold short.
Short Interest Ratio / Days to Cover
2seventy bio has a short interest ratio ("days to cover") of 4.7.
Change versus previous month
Short interest in 2seventy bio has recently increased by 29.71%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
2seventy bio does not currently pay a dividend.
Dividend Growth
2seventy bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TSVT.

3.7

News and Social Media Coverage

News Sentiment
2seventy bio has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for 2seventy bio this week, compared to 3 articles on an average week.
Search Interest
22 people have searched for TSVT on MarketBeat in the last 30 days. This is an increase of 120% compared to the previous 30 days.
MarketBeat Follows
9 people have added 2seventy bio to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, 2seventy bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,143,100.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 2.60% of the stock of 2seventy bio is held by insiders.
Percentage Held by Institutions
93.90% of the stock of 2seventy bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for 2seventy bio are expected to grow in the coming year, from ($1.39) to $0.07 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of 2seventy bio is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of 2seventy bio is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
2seventy bio has a P/B Ratio of 1.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Insiders Exposed

This consistently signaled gains of 453%... 610%... and even 1036%...

It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.

About 2seventy bio Stock (NASDAQ:TSVT)

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

TSVT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TSVT Stock News Headlines

March 26, 2024 | insidertrades.com

Insider Buying: 2seventy bio, Inc. (NASDAQ:TSVT) Director Buys 300,000 Shares of Stock

April 17, 2024 | msn.com

2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why

April 17, 2024 | Priority Gold (Ad)

Biden to Launch “FedNOW” [Move Your Money Now]

Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...

April 15, 2024 | americanbankingnews.com

2seventy bio, Inc. (NASDAQ:TSVT) Short Interest Up 29.7% in March

April 13, 2024 | morningstar.com

2seventy bio Inc Ordinary Shares

April 11, 2024 | americanbankingnews.com

2seventy bio, Inc. (NASDAQ:TSVT) to Post Q1 2024 Earnings of ($0.49) Per Share, Leerink Partnrs Forecasts

April 10, 2024 | investing.com

Citi raises 2Seventy Bio stock target on FDA approval

April 10, 2024 | americanbankingnews.com

Leerink Partnrs Weighs in on 2seventy bio, Inc.'s FY2028 Earnings (NASDAQ:TSVT)

April 17, 2024 | Priority Gold (Ad)

Biden to Launch “FedNOW” [Move Your Money Now]

April 9, 2024 | americanbankingnews.com

Citigroup Raises 2seventy bio (NASDAQ:TSVT) Price Target to $12.00

April 8, 2024 | markets.businessinsider.com

Positive Outlook for 2seventy bio’s ABECMA: Buy Rating Affirmed Amidst Expansion and Competitive Dynamics

April 7, 2024 | markets.businessinsider.com

Buy Rating and High Risk for 2seventy bio: FDA Approval and Market Expansion Fuel Optimistic Outlook

April 5, 2024 | msn.com

Bristol Myers Wins FDA Nod for Abecma

April 5, 2024 | msn.com

FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer

April 5, 2024 | seekingalpha.com

Bristol Myers, 2seventy bio's Abecma approved for earlier line multiple myeloma

April 5, 2024 | finance.yahoo.com

U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

March 20, 2024 | msn.com

2seventy bio appoints Eli Casdin and Charles Newton to its board of directors

March 20, 2024 | businesswire.com

2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors

March 20, 2024 | morningstar.com

Thinking about buying stock in 2Seventy Bio, Verb Technology, Exscientia, MicroCloud Hologram, or Akebia Therapeutics?

March 17, 2024 | marketwatch.com

Bristol Myers, 2seventy Bio's Cancer Treatment Wins FDA Committee Approval

March 16, 2024 | msn.com

Bristol Myers wins FDA AdCom backing for Abecma label expansion

March 15, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: 2seventy bio (TSVT), Immuneering (IMRX)

March 14, 2024 | marketwatch.com

2seventy Bio Shares Fall on Concerns About FDA Panel's Meeting on Abecma Gene Therapy

March 7, 2024 | seekingalpha.com

2Seventy Bio, Inc. (TSVT) Q4 2023 Earnings Call Transcript

March 7, 2024 | msn.com

2seventy bio, Inc. (NASDAQ:TSVT) Q4 2023 Earnings Call Transcript

March 7, 2024 | markets.businessinsider.com

Buy Rating Affirmed for 2seventy bio on FDA Meeting and Strong Financial Outlook

March 7, 2024 | finance.yahoo.com

Downgrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near Term

See More Headlines

Receive TSVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 2seventy bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/05/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:TSVT
CUSIP: N/A
CIK: 1860782
Web: www.2seventybio.com
Phone: 339-499-9300
Fax: N/A
Employees: 274
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $13.17
High Stock Price Target: $26.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +160.2%
Consensus Rating: Hold
Rating Score (0-4): 2.38
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.42)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-217,570,000.00
Net Margins: -216.73%
Pretax Margin: -216.73%
Return on Equity: -59.19%
Return on Assets: -29.67%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.98
Quick Ratio: 3.98

Sales & Book Value

Annual Sales: $100.39 million
Price / Sales: 2.59
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.04 per share
Price / Book: 1.00

Miscellaneous

Outstanding Shares: 51,310,000
Free Float: 49,977,000
Market Cap: $259.63 million
Optionable: Optionable
Beta: 1.84

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Nick Leschly (Age 51)
President & Director
Comp: $1.81M
Dr. Philip D. Gregory D. Phil. (Age 53)
DPHIL, Chief Scientific Officer
Comp: $1.01M
Mr. William D. Baird III (Age 52)
M.B.A., Chief Executive Officer
Comp: $810.83k
Vicki Eatwell
Chief Financial Officer
Jessica Snow
Senior VP of Quality and Head of Operations
Ms. Susan Abu-Absi Ph.D.
Chief Technology Officer
Ms. Teresa L. Jurgensen J.D.
Senior VP, General Counsel & Corporate Secretary
Ms. Kerri Jensen
Head of People & Culture
Ms. Jenn Snyder
Senior Vice President of Corporate Affairs
Dr. Steven Bernstein M.D.
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TSVT Stock Analysis - Frequently Asked Questions

Should I buy or sell 2seventy bio stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 2seventy bio in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TSVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TSVT, but not buy additional shares or sell existing shares.
View TSVT analyst ratings or view top-rated stocks.
What is 2seventy bio's stock price target for 2024?: 8 analysts have issued 1-year price objectives for 2seventy bio's stock. Their TSVT share price targets range from $5.00 to $26.00. On average, they anticipate the company's share price to reach $13.17 in the next twelve months. This suggests a possible upside of 160.2% from the stock's current price.
View analysts price targets for TSVT or view top-rated stocks among Wall Street analysts.
How have TSVT shares performed in 2024?: 2seventy bio's stock was trading at $4.27 at the beginning of the year. Since then, TSVT stock has increased by 18.5% and is now trading at $5.06.
View the best growth stocks for 2024 here.
Are investors shorting 2seventy bio?: 2seventy bio saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 6,810,000 shares, an increase of 29.7% from the March 15th total of 5,250,000 shares. Based on an average daily volume of 1,450,000 shares, the short-interest ratio is currently 4.7 days. Currently, 14.3% of the company's stock are short sold.
View 2seventy bio's Short Interest.
When is 2seventy bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our TSVT earnings forecast.

How were 2seventy bio's earnings last quarter?: 2seventy bio, Inc. (NASDAQ:TSVT) posted its quarterly earnings results on Tuesday, March, 5th. The company reported ($1.11) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.11. The business had revenue of $10.68 million for the quarter, compared to analysts' expectations of $13.91 million. 2seventy bio had a negative trailing twelve-month return on equity of 59.19% and a negative net margin of 216.73%. During the same period in the prior year, the business earned ($0.60) earnings per share.
What ETFs hold 2seventy bio's stock?: ETFs with the largest weight of 2seventy bio (NASDAQ:TSVT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Horizon Kinetics Medical ETF (MEDX) and Goldman Sachs Future Health Care Equity ETF (GDOC).Global X Genomics & Biotechnology ETF (GNOM).
Who are 2seventy bio's major shareholders?: 2seventy bio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wedmont Private Capital (0.17%). Insiders that own company stock include Casdin Capital, Llc, Kynam Capital Management, Lp, Nick Leschly, Nicola Heffron, Philip D Gregory and William D Baird III.
View institutional ownership trends.
How do I buy shares of 2seventy bio?: Shares of TSVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TSVT) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial